IOVA — Iovance Biotherapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresecta… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.10
Market Cap$1.80B
Float388.0M
Shares Outstanding446.5M
Price/Sales (TTM)6.32
vs. Analyst Target+114.6% to analyst PT
Profit Margin-123.90%
Operating Margin (TTM)-113.46%
Revenue (TTM)$286M
Dividend RateNone
Analyst Target Price$8.80 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$260M -$8.7M -$261M
2021 N/A -$328M -$14.0M -$329M
2022 $238,000 -$390M -$21.1M -$378M
2023 $1.2M -$444M -$9.6M -$427M
2024 $164M -$372M $40.1M -$352M
2025 $264M -$391M $256M -$357M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $60.0M -$112M
Sep 2025 $67.5M -$91.3M
Dec 2025 $86.8M -$71.9M
Mar 2026 $71.4M -$79.0M

Ownership & Float

Insider Ownership0.3%
Institutional Ownership67.4%
Short Float29.6%
% of All Funds Holding3.29%
Number of Funds Holding270

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.66Near-term / short-term trend
Weekly40-Week SMA$2.87Medium-term trend
Weekly80-Week SMA$3.53Cyclical trend (business cycle)
Weekly200-Week SMA$6.50Secular trend (multi-year)
Monthly10-Month SMA$2.90Near-term monthly trend
Monthly20-Month SMA$3.96Medium-term monthly trend
Monthly40-Month SMA$6.17Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$1.80 support 2.22x 9 months ago
$4.20 resistance 1.28x 13 months ago
$5.50 resistance 1.28x 14 months ago
$7.50 resistance 1.32x 15 months ago

Historical Earnings Reactions (62 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -2.39% 0.00% 40.32% 18.26% -38.80%
1 Day -0.43% 0.00% 46.77% 31.09% -44.79%
1 Week -2.10% -1.43% 37.10% 44.89% -66.67%
2 Weeks -1.85% -1.86% 41.94% 51.04% -83.33%
1 Month -1.71% -1.09% 45.90% 81.02% -66.67%

Next earnings: July 26, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-4.1%31.3%16
Feb11.5%62.5%16
Mar-1.1%18.8%16
Apr-6.4%31.3%16
May1.2%40.0%15
Jun3.5%40.0%15
Jul22.9%73.3%15
Aug-4.4%26.7%15
Sep-6.1%33.3%15
Oct-3.5%40.0%15
Nov9.6%62.5%16
Dec4.4%62.5%16

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.52% 44.5% 735
Tuesday -0.18% 41.4% 807
Wednesday 0.56% 44.8% 804
Thursday 0.11% 40.2% 789
Friday 0.53% 45.4% 788

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 67.4%

Insider Transactions — Smart Summary

Total insider ownership: 0.3%

12-Month Insider Activity Summary

Total Filings2
Net Value+$64,943.44
Net Shares Change35,600
% of Float0.0%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Kirby Daniel Gordon Chief Commercial Officer +$55,200 1 1 buy
Puri Raj K. Chief Regulatory Officer +$9,743.44 1 1 buy

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-06-06 Kirby Daniel Gordon Chief Commercial Officer +$55,200 Transaction at $1.84, now +122.8%
2025-05-27 Puri Raj K. Chief Regulatory Officer +$9,743.44 Transaction at $1.74, now +135.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Iovance Biotherapeutics Inc (IOVA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for IOVA on Trend Edge →